Gedatolisib is a PAM pathway inhibitor – combining PI3K and mTOR inhibition in one molecule – and in the VIKTORIA-1 trial was ...

In its third big licensing deal of the week, Eli Lilly has tapped into Ascidian Therapeutics' RNA-editing capabilities with a ...

In the latest part of its plan to cut barriers to cell and gene therapy (CGT) development, the FDA has published draft ...

Shares in French biotech Abivax tumbled more than 30% today, after it announced phase 3 data with ulcerative colitis (UC) ...

The SUPPORT+ mobile app, developed by researchers led by Dr Wing-Lok Chan at Hong Kong University, delivers weekly reminders ...

A three-drug regimen incorporating AstraZeneca's immune checkpoint inhibitors Imfinzi and Imjudo has reduced the risk of ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...

AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will ...

In AL amyloidosis, abnormal plasma cells in the bone marrow produce misfolded proteins that clump together clump together ...

Eli Lilly looks set to extend the reach of its RET inhibitor Retevmo in RET-mutated tumours, as the LIBRETTO-432 trial shows ...

Sobi's $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout ...

Bristol Myers Squibb has high hopes for its celmod programme for blood cancers, and a phase 3 readout – for mezigdomide in ...